Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Zimmer Biomet has seen a strong operating performance despite years of stagnation, making its shares compelling. The company's valuation has become more reasonable, with revenues trending at around $7.3 billion and adjusted earnings reported at $7.50 per share. The impact of GLP-1 drugs on demand for Zimmer Biomet's products raises concerns about future growth.

Zimmer Biomet: Still Many Questions After A Solid Year So Far

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt

WARSAW, Ind. , Nov. 16, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 2023 Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 9:00 a.m.

Zimmer Biomet to Present at the 2023 Piper Sandler Healthcare Conference

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Keri Mattox – Chief Communications and Administration Officer Ivan Tornos – President and Chief Executive Officer Suky Upadhyay – Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Drew Ranieri – Morgan Stanley Matt Taylor – Jefferies Shagun Singh – RBC Capital Markets Josh Jennings – TD Cowen Larry Biegelsen – Wells Fargo Chris Pasquale – Nephron Travis Steed – Bank of America Vijay Kumar – Evercore ISI Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet's Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today November 7.

Zimmer Biomet Holdings, Inc. (ZBH) Q3 2023 Earnings Call Transcript

Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall

The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.65 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.58 per share a year ago.

Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates

Zimmer Biomet Holdings Inc on Tuesday beat Wall Street estimates for third-quarter profit, as a rebound in knee surgeries lifted demand for the medical device maker's products.

Zimmer Biomet beats quarterly profit estimates on knee procedure strength

Third quarter net sales of $1.754 billion increased 5.0% and 4.7% on a constant currency1 basis Third quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $1.65 The Company updates 2023 reported revenue guidance due to currency expectations and reaffirms 2023 constant currency revenue growth and adjusted1 earnings per share financial guidance WARSAW, Ind. , Nov. 7, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2023.

Zimmer Biomet Announces Third Quarter 2023 Financial Results

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Zimmer Biomet (ZBH) Might Surprise This Earnings Season

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.

Stay Ahead of the Game With Zimmer (ZBH) Q3 Earnings: Wall Street's Insights on Key Metrics

Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.

Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?

AstraZeneca

STAAR Surgical

Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healthcare.

These healthcare stocks should come to life as boomers live their golden years

Abbott Labs

Investors looking for stocks in the Medical - Products sector might want to consider either Zimmer Biomet (ZBH) or Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?

ZBH or ABT: Which Is the Better Value Stock Right Now?

Gilead Sciences

Haleon PLC

Medtronic

Merck

Novartis

West Pharmaceutical Services

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

7 Healthcare Stocks to invest in for a Healthy Future

Baxter

DexCom

Penumbra

Insulet

ResMed

Some investors have worried that new weight-loss drugs could undermine demand for some medical devices.

6 Medical Device Stocks Primed to Bounce Back

Align Technology

Keurig Dr Pepper Inc

Twilio

Ulta Beauty

We have narrowed our search to five large-cap (market capital > $10 billion) stocks with attractive valuations. These stocks are: TWLO, KDP, ULTA, ALGN, ZBH.

5 Large-Cap Stocks to Buy on the Dip for Q4 2023

Corteva Inc

Kenvue

NextEra Energy

Sherwin-Williams

Exxon Mobil

YUM! Brands

While publicly traded securities that benefit from significant upside potential usually carry a higher-risk profile, with high-growth S&P 500 stocks, you can almost get the best of both worlds. To be fair, we need to set some expectations.

7 High-Growth S&P 500 Stocks to Buy Now

Boston Scientific

Haemonetics

Stryker

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

5 Medical Product Stocks to Buy Amid Industry Recovery

WARSAW, Ind. , Oct. 10, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Tuesday, November 7, 2023 at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2023 Financial Results

Illumina

Johnson & Johnson

Moderna

UnitedHealth Group

With the current sector-wide downturn, it's not surprising that several large healthcare stocks are currently undervalued, relative to their intrinsic value, based on their fundamentals, cash flows, and future earnings potential.

3 Undervalued Healthcare Stocks to Watch as Sector Struggles

Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.

Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes

Zimmer Biomet Holdings outlined strategies to gain market share in the knee sector and foster innovation in hip products. ZBH has raised its 2023 growth forecast, reflecting confidence in its strategic initiatives. It also reported strong financial performance in Q2 2023, with increased sales and stable EPS.

Zimmer Biomet Holdings: Growth Strategies For 2023 Instill Confidence

WARSAW, Ind., Sept. 5, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced key updates to the Company's Executive Leadership Team. Wilfred van Zuilen has been promoted to Group President, EMEA; Mark Bezjak was promoted to President of the Americas; and Chief Science, Technology and Innovation Officer Nitin Goyal, M.D. has been appointed to the Executive Leadership Team, all reporting directly to President and Chief Executive Officer Ivan Tornos.

News for Zimmer Biomet Hlds Stock (ZBH)